Pharma
-
Scott Olson via Getty Images
Obesity drugsLilly’s triple-acting obesity drug hits goal in Phase 3 trial
Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.
By Jonathan Gardner • May 21, 2026 -
Permission granted by Bristol Myers Squibb
Q&A // Brain drug revivalIn Alzheimer’s, Bristol Myers sees big promise beyond amyloid
Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.
By Jacob Bell • May 21, 2026 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Permission granted by Bristol-Myers Squibb
Bristol Myers deepens AI investment with Anthropic deal
The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers have used to adopt the technology across many day-to-day activities.
By Kristin Jensen • May 20, 2026 -
Getty Images
News roundupImmunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.
By BioPharma Dive staff • May 20, 2026 -
Christopher Furlong via Getty Images
FDA approves AstraZeneca’s new kind of hypertension drug
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.
By Jacob Bell • May 18, 2026 -
Getty Images
China competitionMerck ADC, licensed from China, hits mark in first big global trial
The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.
By Jonathan Gardner • May 18, 2026 -
Anna Moneymaker via Getty Images
Trump administrationSupreme Court preserves access to abortion pill by mail
The ruling maintains access to the drug while litigation continues. Mifepristone can still be prescribed at pharmacies or by mail without requiring in-person visits.
By Sydney Halleman • May 15, 2026 -
Getty Images
India’s pharma industry is going global. But can it catch up to China?
A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.
By Kelly Bilodeau • May 15, 2026 -
Alyssa Eckel-Martin/BioPharma Dive
Sponsored by McKesson[Podcast] Closing the Distance in Cancer Care
This podcast episode explores the critical role community oncology plays in the U.S. healthcare system and why supporting its growth and autonomy matters for patients and providers.
May 13, 2026 -
Douglas Olivares via Getty Images
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.
By Delilah Alvarado • May 12, 2026 -
Getty Images
China competitionBristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.
By Ben Fidler • May 12, 2026 -
Getty Images
China competitionGSK cuts deal with Sino to broaden reach of hepatitis B drug
The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.
By Delilah Alvarado • May 11, 2026 -
Getty Images
Biotech layoffs are easing, but is the worst over?
BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.
By Kelly Bilodeau • May 11, 2026 -
TopRight
Sponsored by Middlesex CountyThe capacity crunch in biopharma is a location problem
Cell and gene therapies aren’t limited by ideas—they’re limited by where they’re built. See how “ready-now” locations change the math on scaling.
May 11, 2026 -
Sponsored by Marken
Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies
The future of medicine is here. See how specialized logistics are saving lives with next-gen cell and gene therapies.
By Marken, UPS Healthcare Precision Logistics • May 11, 2026 -
Justin Sullivan via Getty Images
Lilly, Gilead lead pharma’s M&A boom
Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.
By Kelly Bilodeau • May 8, 2026 -
Maja Hitij via Getty Images
Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
By Delilah Alvarado • May 6, 2026 -
Permission granted by Novo Nordisk
Obesity drugsNovo hikes guidance on Wegovy pill’s fast sales start
In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.
By Kristin Jensen • May 6, 2026 -
Getty Images
News roundup
Avalo shares spike on skin drug data; BioNTech to cut staff
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.
By Ben Fidler • May 6, 2026 -
Permission granted by QIAGEN
Sponsored by QIAGEN Digital InsightsWhat is your AI drug repurposing strategy missing?
Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.
By Iman Bhattacharya • May 4, 2026 -
Getty Images
Merck still sees ‘compelling’ outlook for Terns leukemia drug
Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.
By Jonathan Gardner • April 30, 2026 -
Courtesy of UniQure
UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy
News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S.
By Delilah Alvarado • April 30, 2026 -
Courtesy of Eli Lilly
Obesity drugsLilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for both profit and revenue.
By Kristin Jensen • April 30, 2026 -
Getty Images
Pfizer deals extend patent life for a top-selling rare disease drug
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
By Ben Fidler • April 28, 2026 -
Courtesy of Boehringer Ingelheim
Obesity drugsBoehringer dual-acting obesity shot hits mark in Phase 3 trial
Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.
By Jonathan Gardner • April 28, 2026
